FrancophonIA/ELRC3.0 huggingface dataset:
English: Patients followed a 4- to 5-week dose-titration schedule starting at 20 mg and increasing to 50 mg, 100 mg, 200 mg and finally 400 mg once daily.
Croatian: Bolesnici su slijedili raspored titracije doze u trajanju od 4 do 5 tjedana, počevši dozom od 20 mg koja se zatim povećavala na 50 mg, 100 mg, 200 mg i naposljetku 400 mg jedanput na dan.
English: Venetoclax is highly bound to human plasma protein with unbound fraction in plasma <0.01 across a concentration range of 1-30 µM (0.87-26 µg/ml).
Croatian: Venetoklaks se u velikoj mjeri vezuje za humane proteine u plazmi, pa udio nevezanog lijeka u plazmi kod raspona koncentracija od 1 do 30 µM (0,87 - 26 µg/ml) iznosi < 0,01.
English: Following multiple oral administrations, maximum plasma concentration of venetoclax was reached 5-8 hours after dose.
Croatian: Apsorpcija Nakon višestruke peroralne primjene, maksimalna plazmatska koncentracija venetoklaksa postignuta je 5 - 8 sati nakon primjene doze.
English: There is no specific antidote for venetoclax.
Croatian: Ne postoji specifičan protulijek za venetoklaks.
English: No TLS with clinical consequences such as acute renal failure, cardiac arrhythmias or sudden death and/or seizures was observed in these patients.
Croatian: U tih bolesnika nije opažen TLS s kliničkim posljedicama poput akutnog zatajenja bubrega, srčanih aritmija ili iznenadne smrti i/ili napadaja.
English: Changes in electrolytes consistent with TLS that require prompt management can occur as early as 6 to 8 hours following the first dose of venetoclax and at each dose increase.
Croatian: Promjene u vrijednostima elektrolita koje odgovaraju TLS-u i zahtijevaju neodgodivo zbrinjavanje mogu nastupiti već 6 do 8 sati nakon prve doze venetoklaksa i pri svakom povećanju doze.
English: The median duration of grade 3 or 4 neutropenia was 8 days (range: 1-712 days).
Croatian: Medijan trajanja neutropenije 3. ili 4. stupnja iznosio je 8 dana (raspon: 1 - 712 dana).
English: Do not use this medicine after the expiry date which is stated on the carton and blister after EXP.
Croatian: Ovaj lijek se ne smije upotrijebiti nakon isteka roka valjanosti navedenog na kutiji i blisteru iza oznake 'Rok valjanosti' ili 'EXP'.
English: Drink the same amount of water (at least 1.5 to 2 litres daily) two days before and on the day that your dose is increased.
Croatian: Istu tu količinu vode (najmanje 1,5 - 2 litre na dan) pijte i dva dana prije te na dan povećanja doze.
English: Patients should be adequately hydrated during the dose-titration phase to reduce the risk of TLS.
Croatian: Potrebna je odgovarajuća hidracija bolesnika tijekom faze titracije doze kako bi se smanjio rizik od TLS-a.
English: Overexpression of BCL-2 has been demonstrated in CLL cells where it mediates tumour cell survival and has been associated with resistance to chemotherapeutics.
Croatian: Dokazana je prekomjerna ekspresija BCL-2 u stanicama KLL-a, u kojima posreduje u preživljenju tumorskih stanica, i povezuje se s rezistencijom na kemoterapeutike.
English: Venetoclax binds directly to the BH3-binding groove of BCL-2, displacing BH3 motif-containing pro-apoptotic proteins like BIM, to initiate mitochondrial outer membrane permeabilization (MOMP), caspase activation, and programmed cell death.
Croatian: Venetoklaks se vezuje izravno na utor koji veže BH3 proteina BCL-2 te tako istiskuje proapoptotske proteine koji sadrže motiv BH3, kao što je BIM, kako bi započeo permeabilizaciju vanjske membrane mitohondrija, aktivaciju kaspaze i programiranu staničnu smrt.
English: The recommended dose of venetoclax is 400 mg once daily.
Croatian: Preporučena doza venetoklaksa je 400 mg jedanput na dan.
English: • medicines that prevent blood clots, warfarin, dabigatran
Croatian: • lijekove koji sprječavaju nastanak krvnih ugrušaka - varfarin, dabigatran
English: After a single oral administration of 200 mg radiolabeled [14C]-venetoclax to healthy subjects, >99.9% of the dose was recovered in faeces and <0.1% of the dose was excreted in urine within 9 days.
Croatian: Nakon jednokratne peroralne primjene 200 mg radioaktivno označenog [14C]-venetoklaksa zdravim ispitanicima, > 99,9% doze pronađeno je u fecesu, a < 0,1% doze izlučilo se kroz mokraću unutar 9 dana.
English: The overall safety profile of Venclyxto is based on data from 546 patients with CLL treated in clinical trials with venetoclax in combination with rituximab or as monotherapy.
Croatian: Sveukupan sigurnosni profil lijeka Venclyxto temelji se na podacima prikupljenima u 546 bolesnika s KLL-om liječenih u kliničkim ispitivanjima venetoklaksa u kombinaciji s rituksimabom ili u monoterapiji.
English: This is because they can increase the amount of venetoclax in your blood.
Croatian: Naime, navedeno voće može povećati količinu venetoklaksa u krvi.
English: Venetoclax steady state AUC increased proportionally over the dose range of 150-800 mg.
Croatian: AUC venetoklaksa u stanju dinamičke ravnoteže povećavao se proporcionalno u rasponu doza od 150 do 800 mg.
English: Venetoclax is predominantly metabolised by CYP3A.
Croatian: Venetoklaks se pretežno metabolizira putem CYP3A.
English: CLL is a type of cancer affecting white blood cells called lymphocytes and the lymph nodes.
Croatian: KLL je vrsta raka koja pogađa bijele krvne stanice zvane limfociti i limfne čvorove.
English: Venetoclax can cause rapid reduction in tumour, and thus poses a risk for TLS in the initial 5-week dose-titration phase.
Croatian: Venetoklaks može uzrokovati brzo smanjenje tumora i stoga predstavlja rizik od TLS-a tijekom početne 5-tjedne faze titracije doze.
English: • If it is more than 8 hours since the time you usually take your dose, do not take the dose that day.
Croatian: • Ako je od vremena kada obično uzimate dozu prošlo više od 8 sati, nemojte uzeti dozu taj dan.
English: This is because Venclyxto may affect the way some other medicines work.
Croatian: Naime, Venclyxto može utjecati na način djelovanja nekih drugih lijekova.
English: • If it is less than 8 hours since the time you usually take your dose, take it as soon as possible.
Croatian: • Ako je od vremena kada obično uzimate dozu prošlo manje od 8 sati, uzmite dozu što je prije moguće.
English: • irregular heart beat
Croatian: • nepravilne otkucaje srca
English: The 5-week dose-titration schedule is designed to gradually reduce tumour burden (debulk) and decrease the risk of tumour lysis syndrome.
Croatian: 5-tjedni raspored titracije doze osmišljen je tako da postupno smanji opterećenje tumorskom masom (engl. debulk) i smanji rizik od sindroma lize tumora.
English: Based on venetoclax large volume of distribution and extensive protein binding, dialysis is unlikely to result in significant removal of venetoclax.
Croatian: S obzirom na velik volumen distribucije venetoklaksa i njegovo opsežno vezivanje za proteine, malo je vjerojatno da će dijaliza u značajnoj mjeri ukloniti venetoklaks.
English: A randomised (1:1), multicenter, open-label phase 3 study evaluated the efficacy and safety of Venclyxto + rituximab versus BR in patients with previously treated CLL.
Croatian: U randomiziranom (1:1), multicentričnom, otvorenom ispitivanju faze 3 ocjenjivale su se djelotvornost i sigurnost lijeka Venclyxto + rituksimaba u odnosu na protokol BR u bolesnika s prethodno liječenim KLL-om.
English: This is because serious and life-threatening effects can occur when Venclyxto is taken with these medicines:
Croatian: Naime, mogu nastupiti ozbiljni i po život opasni učinci kada se Venclyxto primjenjuje sa sljedećim lijekovima:
English: Median OS and DOR were not reached with median follow-up of approximately 14.3 months for Arm A and 14.7 months for Arm B.
Croatian: Medijan OS-a i trajanja odgovora nisu dosegnuti uz medijan praćenja od približno 14,3 mjeseca u skupini A i 14,7 mjeseci u skupini B.
English: Co-administration of bile acid sequestrants with venetoclax is not recommended as this may reduce the absorption of venetoclax.
Croatian: Istodobna primjena sekvestranata žučne kiseline s venetoklaksom se ne preporučuje jer to može smanjiti apsorpciju venetoklaksa.
English: It is unknown whether venetoclax or its metabolites are excreted in human milk.
Croatian: Nije poznato izlučuju li se venetoklaks ili njegovi metaboliti u majčino mlijeko.
English: You will begin treatment with Venclyxto at a low dose for 1 week.
Croatian: Liječenje lijekom Venclyxto započet ćete primjenom male doze tijekom tjedan dana.
English: Of the 194 patients with previously treated CLL who received venetoclax in combination with rituximab, 50% were 65 years or older.
Croatian: Među 194 bolesnika s prethodno liječenim KLL-om koji su primali venetoklaks u kombinaciji s rituksimabom, njih 50% bilo je u dobi od 65 ili više godina.
English: No human data on the effect of venetoclax on fertility are available.
Croatian: Nema dostupnih podataka o učinku venetoklaksa na plodnost ljudi.
English: Signs may include fever, chills, feeling weak or confused, cough, pain or burning feeling when passing urine.
Croatian: Znakovi mogu uključivati vrućicu, zimicu, slabost ili smetenost, kašalj te bol ili žarenje pri mokrenju.
English: The active substance is venetoclax.
Croatian: Djelatna tvar je venetoklaks.
English: With venetoclax + rituximab treatment, febrile neutropenia was reported in 4% of patients, grade ≥3 infections in 18%, and serious infections in 21% of patients.
Croatian: Kod liječenja venetoklaksom + rituksimabom, febrilna neutropenija prijavljena je u 4% bolesnika, infekcije ≥ 3. stupnja u 18% bolesnika, a ozbiljne infekcije u 21% bolesnika.
English: The mean blood-to-plasma ratio was 0.57.
Croatian: Srednja vrijednost omjera distribucije između krvi i plazme iznosila je 0,57.
English: Based on population pharmacokinetic analysis, gastric acid reducing agents (e.g., proton pump inhibitors, H2-receptor antagonists, antacids) do not affect venetoclax bioavailability.
Croatian: Prema populacijskoj farmakokinetičkoj analizi, lijekovi koji smanjuju želučanu kiselinu (npr. inhibitori protonske pumpe, antagonisti H2-receptora, antacidi) ne utječu na bioraspoloživost venetoklaksa.
English: - Women of childbearing age must use a highly effective method of contraception during treatment and for at least 30 days after receiving Venclyxto to avoid becoming pregnant.
Croatian: - Žene reproduktivne dobi moraju koristiti visoko učinkovitu metodu kontracepcije tijekom liječenja i još najmanje 30 dana nakon liječenja lijekom Venclyxto kako bi izbjegle trudnoću.
English: Venetoclax is not an inhibitor of UGT1A4, UGT1A6, UGT1A9 and UGT2B7.
Croatian: Venetoklaks nije inhibitor UGT1A4, UGT1A6, UGT1A9 ni UGT2B7.
English: This is called tumour lysis syndrome (TLS).
Croatian: To se naziva sindromom lize tumora (TLS).
English: The starting dose is 20 mg of venetoclax once daily for 7 days.
Croatian: Početna doza je 20 mg venetoklaksa jedanput na dan tijekom 7 dana.
English: 27.2 (21.9, NR)
Croatian: 27,2 (21,9; NP)
English: Patients continued to receive venetoclax 400 mg once daily until disease progression or unacceptable toxicity was observed.
Croatian: Bolesnici su nastavili primati venetoklaks u dozi od 400 mg jedanput na dan do progresije bolesti ili pojave neprihvatljive toksičnosti.
English: The M27 metabolite was negative for genotoxicity in the bacterial mutagenicity and chromosomal aberration assays.
Croatian: Metabolit M27 bio je negativan na genotoksičnost u testu mutagenosti na bakterijama i testu kromosomskih aberacija.
English: Serious infections including events of sepsis with fatal outcome have been reported.
Croatian: Prijavljene su ozbiljne infekcije, uključujući slučajeve sepse sa smrtnim ishodom.
English: MURANO was a randomised, controlled trial in which 194 patients with previously treated CLL received venetoclax in combination with rituximab.
Croatian: Ispitivanje MURANO bilo je randomizirano, kontrolirano ispitivanje u kojem su 194 bolesnika s prethodno liječenim KLL-om primala venetoklaks u kombinaciji s rituksimabom.
English: Co-administration of venetoclax with other strong CYP3A4 inhibitors is predicted to increase venetoclax AUC by on average 5.8- to 7.8-fold.
Croatian: Predviđa se da će istodobna primjena venetoklaksa s drugim snažnim inhibitorima CYP3A4 povećati AUC venetoklaksa u prosjeku 5,8 do 7,8 puta.
English: There is no information about the safety of venetoclax in pregnant women.
Croatian: Nema podataka o sigurnosti primjene venetoklaksa u trudnica.
English: Figure 2: Kaplan-Meier curves of overall survival (intent-to-treat population) in MURANO
Croatian: Slika 2: Kaplan-Meierove krivulje ukupnog preživljenja (populacija predviđena za liječenje ) u ispitivanju MURANO
English: Venclyxto film-coated tablets are supplied in PVC/PE/PCTFE aluminium foil blisters containing either 1, 2 or 4 film-coated tablets.
Croatian: Venclyxto filmom obložene tablete dolaze u blisterima od PVC/PE/PCTFE plastike i aluminijske folije sadržavajući 1, 2 ili 4 filmom obložene tablete.
English: Arm A (ibrutinib failures) (N=91)
Croatian: Skupina A (bolesnici bez odgovora na ibrutinib) (N=91)
English: There were no overall differences in safety or efficacy observed between older and younger patients in the combination study with venetoclax + rituximab and the monotherapy studies.
Croatian: Sveukupno nisu opažene razlike u sigurnosti i djelotvornosti između starijih i mlađih bolesnika ni u ispitivanju kombinacije venetoklaksa + rituksimaba ni u ispitivanjima monoterapije.
English: In venetoclax clinical studies, patients with any measurable lymph node ≥10 cm or those with both an ALC ≥25 x 109/l and any measurable lymph node ≥5 cm were hospitalised to enable more intensive hydration and monitoring for the first day of dosing at 20 mg and 50 mg during the titration phase (see section 4.2).
Croatian: U kliničkim ispitivanjima venetoklaksa, bolesnici s bilo kojim mjerljivim limfnim čvorom ≥ 10 cm ili oni koji su imali i apsolutan broj limfocita ≥ 25 x 109/l i bilo koji mjerljiv limfni čvor ≥ 5 cm bili su hospitalizirani kako bi se omogućila intenzivnija hidracija i praćenje tijekom prvog dana primjene doze od 20 mg i doze od 50 mg tijekom faze titracije (vidjeti dio 4.2).
English: If any of the above apply to you, or you are not sure, talk to your doctor, pharmacist, or nurse before taking this medicine.
Croatian: Ako se bilo što od navedenoga odnosi na Vas, ili niste sigurni, obratite se liječniku, ljekarniku ili medicinskoj sestri prije nego uzmete ovaj lijek.
English: M27 was identified as a major metabolite in plasma with an inhibitory activity against BCL-2 that is at least 58-fold lower than venetoclax in vitro.
Croatian: Kao glavni metabolit u plazmi identificiran je M27, čije je inhibicijsko djelovanje na BCL-2 najmanje 58 puta manje od djelovanja venetoklaksa in vitro.
English: You may feel tired after taking Venclyxto, which may affect your ability to drive or use tools or machines.
Croatian: Možda ćete se osjećati umorno tijekom liječenja lijekom Venclyxto, što može utjecati na Vašu sposobnost upravljanja vozilima, rukovanja alatima ili rada sa strojevima.
English: If a bile acid sequestrant is to be co-administered with venetoclax, the SmPC for the bile acid sequestrant should be followed to reduce the risk for an interaction, and venetoclax should be administered at least 4-6 hours after the sequestrant.
Croatian: Ako se sekvestrant žučne kiseline mora primijeniti istodobno s venetoklaksom, potrebno je slijediti upute u Sažetku opisa svojstava lijeka za taj sekvestrant žučne kiseline kako bi se smanjio rizik od interakcije, a venetoklaks treba primijeniti najmanje 4 - 6 sati nakon sekvestranta.
English: No dose adjustment is recommended in patients with mild or moderate hepatic impairment.
Croatian: Ne preporučuje se prilagođavati dozu u bolesnika s blagim ili umjerenim oštećenjem jetrene funkcije.
English: Patients should be monitored more closely for signs and symptoms of TLS.
Croatian: Bolesnike treba pažljivije nadzirati zbog mogućih znakova i simptoma
English: Venetoclax is not expected to inhibit OATP1B3, OCT1, OCT2, OAT1, OAT3, MATE1 or MATE2K at clinically relevant concentrations.
Croatian: Ne očekuje se da će venetoklaks inhibirati prijenosnike OATP1B3, OCT1, OCT2, OAT1, OAT3, MATE1 ili MATE2K pri klinički značajnim koncentracijama.
English: Administration with a low-fat meal increased venetoclax exposure by approximately 3.4-fold and administration with a high-fat meal increased venetoclax exposure by 5.1- to 5.3-fold compared to fasting conditions.
Croatian: Primjena uz obrok s niskim udjelom masnoća povećala je izloženost venetoklaksu približno 3,4 puta, dok je primjena uz obrok s visokim udjelom masnoća povećala izloženost venetoklaksu 5,1 do 5,3 puta u usporedbi s primjenom natašte.
English: Grade 3 neutropenia was reported in 32% of patients and grade 4 neutropenia in 26% of patients.
Croatian: Neutropenija 3. stupnja prijavljena je u 32% bolesnika, a neutropenija 4. stupnja u 26% bolesnika.
English: Reduced renal function (creatinine clearance [CrCl] <80 ml/min) further increases the risk.
Croatian: Smanjena bubrežna funkcija (klirens kreatinina [CrCl] < 80 ml/min) dodatno povećava taj rizik.
English: Venclyxto is a cancer medicine that contains the active substance venetoclax.
Croatian: Venclyxto je lijek za liječenje raka koji sadrži djelatnu tvar venetoklaks.
English: No effects on fertility were observed in fertility and early embryonic development studies in male and female mice.
Croatian: Nisu primijećeni učinci na plodnost u ispitivanjima utjecaja na plodnost i rani razvoj embrija u mužjaka i ženki miševa.
English: Based on a population pharmacokinetic analysis that included 74 subjects with mild hepatic impairment, 7 subjects with moderate hepatic impairment and 442 subjects with normal hepatic function, venetoclax exposures are similar in subjects with mild and moderate hepatic impairment and normal hepatic function.
Croatian: Prema populacijskoj farmakokinetičkoj analizi koja je obuhvatila 74 ispitanika s blagim oštećenjem jetrene funkcije, 7 ispitanika s umjerenim oštećenjem jetrene funkcije i 442 ispitanika s normalnom jetrenom funkcijom, izloženost venetoklaksu slična je u ispitanika s blagim i umjerenim oštećenjem jetrene funkcije i onih s normalnom jetrenom funkcijom.
English: Reduced renal function (CrCl <80 ml/min) further increases the risk.
Croatian: Smanjena bubrežna funkcija (CrCl < 80 ml/min) dodatno povećava taj rizik.
English: This is because it has not been studied in these age groups.
Croatian: Naime, lijek se nije ispitivao u tim dobnim skupinama.
English: No clinical TLS was observed in patients who followed the current 5-week dose-titration schedule and TLS prophylaxis and monitoring measures (see section 4.2).
Croatian: Nije opažen klinički TLS u bolesnika koji su se pridržavali trenutno propisanog 5-tjednog rasporeda titracije doze te mjera za profilaksu i kontrolu TLS-a (vidjeti dio 4.2).
English: In total, 130 patients in the venetoclax + rituximab arm completed 2 years of venetoclax treatment without progression.
Croatian: Ukupno je 130 bolesnika u skupini liječenoj venetoklaksom + rituksimabom dovršilo 2 godine liječenja venetoklaksom bez progresije bolesti.
English: Grade 3 or 4 neutropenia has been reported in patients treated with venetoclax in the combination study with rituximab (GO28667/MURANO) and in the monotherapy studies (see section 4.8).
Croatian: Neutropenija 3. ili 4. stupnja prijavljena je u bolesnika liječenih venetoklaksom u ispitivanju kombinacije s rituksimabom (GO28667/MURANO) i ispitivanjima monoterapije (vidjeti dio 4.8).
English: When resuming treatment after interruption due to TLS, the instructions for prevention of TLS should be followed (see “Prevention of tumour lysis syndrome” above).
Croatian: Kada se liječenje nastavlja nakon privremenog prekida zbog TLS-a, treba se pridržavati uputa za prevenciju TLS-a (vidjeti odlomak „Prevencija sindroma lize tumora“ u prethodnom tekstu).
English: Efficacy results for the pre-specified primary analysis (data cut-off date 8 May 2017) were also assessed by an Independent Review Committee (IRC) demonstrating a statistically significant 81% reduction in the risk of progression or death for patients treated with venetoclax + rituximab (hazard ratio: 0.19 [95% CI: 0.13,
Croatian: Rezultate za djelotvornost za unaprijed specificiranu primarnu analizu (završni datum prikupljanja podataka: 8. svibnja 2017.) ocijenilo je i neovisno ocjenjivačko povjerenstvo, koje je utvrdilo statistički značajno smanjenje rizika od progresije bolesti ili smrti za 81% u bolesnika liječenih venetoklaksom + rituksimabom (omjer hazarda: 0,19 [95% CI: 0,13; 0,28]; P < 0,0001).
English: • lower number of white blood cells called lymphocytes
Croatian: • smanjen broj bijelih krvnih stanica koje se zovu limfociti
English: A 17p deletion was detected in 26.9% of patients, TP53 mutations in 26.3%, 11q deletion in 36.5%, and unmutated IgVH gene in 68.3%.
Croatian: Delecija 17p pronađena je u 26,9% bolesnika, mutacije gena TP53 u 26,3% bolesnika, delecija 11q u 36,5% bolesnika, a nemutiran gen IgVH u 68,3% bolesnika.
English: 27.5 (26.5, NR)
Croatian: 27,5 (26,5; NP)
English: Venetoclax in combination with rituximab for the treatment of patients with CLL who have received at least one prior therapy - study GO28667 (MURANO)
Croatian: Venetoklaks u kombinaciji s rituksimabom za liječenje bolesnika s KLL-om koji su primili najmanje jednu prethodnu terapiju - ispitivanje GO28667 (MURANO)
English: The primary efficacy endpoint was overall response rate (ORR) as assessed by an Independent Review Committee (IRC) using the IWCLL updated NCI-WG guidelines (2008).
Croatian: Primarna mjera ishoda za djelotvornost bila je stopa ukupnog odgovora (ORR) prema ocjeni neovisnog ocjenjivačkog povjerenstva na temelju NCI-WG smjernica koje je ažurirao IWCLL (2008.).
English: Pre-dose: For all patients, blood chemistries should be assessed prior to the initial dose to evaluate kidney function and correct pre-existing abnormalities.
Croatian: Prije primjene: Prije primjene prve doze, u svih bolesnika treba odrediti biokemijske parametre krvi kako bi se ocijenila bubrežna funkcija i korigirala postojeća odstupanja od normalnih vrijednosti.
English: Rituximab should be administered after the patient has completed the dose-titration schedule and has received the recommended daily dose of 400 mg venetoclax for 7 days.
Croatian: Rituksimab treba primijeniti nakon što bolesnik dovrši titraciju doze prema rasporedu i primi preporučenu dnevnu dozu venetoklaksa od 400 mg tijekom 7 dana.
English: • Do not chew, crush, or break the tablets
Croatian: • Nemojte ih žvakati, drobiti ni lomiti.
English: 24-month PFS estimate (95% CI) CI = confidence interval; NR = not reached aStratified P-value.
Croatian: CI (engl. confidence interval) = interval pouzdanosti; NP = nije postignuto aStratificirana P-vrijednost.
English: Tumour lysis syndrome is an important identified risk when initiating venetoclax.
Croatian: Sindrom lize tumora važan je identificiran rizik pri uvođenju liječenja venetoklaksom.
English: Fatigue has been reported in some patients taking venetoclax and should be considered when assessing a patient's ability to drive or operate machines.
Croatian: nekih bolesnika koji su uzimali venetoklaks prijavljen je umor, što treba uzeti u obzir pri ocjenjivanju bolesnikove sposobnosti upravljanja vozilima ili rada sa strojevima.
English: Also some other medicines can affect the way Venclyxto works.
Croatian: Isto tako, neki drugi lijekovi mogu utjecati na način djelovanja lijeka Venclyxto.
English: Your dose may need to be adjusted for side effects.
Croatian: Možda će Vam trebati prilagoditi dozu zbog nuspojava.
English: Anti-hyperuricaemic agents should be administered 2 to 3 days prior to starting treatment with venetoclax in patients with high uric acid levels or at risk of TLS and may be continued through the titration phase.
Croatian: Lijekovi za hiperuricemiju Lijekove za hiperuricemiju treba primjenjivati 2 do 3 dana prije početka liječenja venetoklaksom u bolesnika koji imaju visoke vrijednosti mokraćne kiseline ili rizik od TLS-a, a njihova se primjena može nastaviti i tijekom faze titracije.